Martine Elia

Mrs. Martine Elia


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
Sandeep SehdevSandeep Sehdev
Sandeep Sehdev
JGJoanna Gotfrit
Joanna Gotfrit
MEMartine Elia
Martine Elia
BSBarry D. Stein
Barry D. Stein
Canada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to identify studies associated with the clinical, economic, and quality of life impacts of delayed access to oncology drugs. Using MEDLINE/PubMed databases and snowballing, four unique records met the eligibility criteria. Results revealed that clinical outcomes were the most impacted by systemic delays in access to oncology drugs (e.g., life years lost, overall survival, and progression-free survival). The four articles retrieved by the TLR specifically illustrated that a substantial number of life years could potentially be saved by increasing systemic efficiency regarding the development, approval, and reimbursement processes of new drugs for advanced malignancies. It is imperative that initiatives are put in place to improve the performance and speed of Canadian drug regulatory and health technology assessment (HTA) processes, especially for new cancer therapeutics. The proposed solutions in this paper include better coordination between HTA and Canadian payers to harmonize coverage decisions, international collaborations, information sharing, and national standards for timeliness in oncology drug access.

7 August 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
WEWilliam Kenneth Evans
William Kenneth Evans
PTPam Takhar
Pam Takhar
VMValerie McDonald
Valerie McDonald
MEMartine Elia
Martine Elia
LBLouise Binder
Louise Binder
KCKelvin Chan
Kelvin Chan
The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration established the Engagement Working Group (WG) to ensure that all key stakeholders had an opportunity to provide input into the development and implementation of the CanREValue Real-World Evidence (RWE) Framework. Two consultations were held in 2021 to solicit patient perspectives on key policy and data access issues identified in the interim policy and data WG reports. Over 30 individuals, representing patients, caregivers, advocacy leaders, and individuals engaged in patient research were invited to participate. The consultations provided important feedback and valuable lessons in patient engagement. Patient leaders actively shaped the process and content of the consultation. Breakout groups facilitated by patient advocacy leaders gave the opportunity for open and thoughtful contributions from all participants. Important recommendations were made: the RWE framework should not impede access to new drugs; it should be used to support conditional approvals; patient relevant endpoints should be captured in provincial datasets; access to data to conduct RWE should be improved; and privacy issues must be considered. The manuscript documents the CanREValue experience of engaging patients in a consultative process and the useful contributions that can be achieved when the processes to engage are guided by patients themselves.

19 March 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
JPJulie Patenaude
Julie Patenaude
ALAriane Légaré
Ariane Légaré
FDFlorence Dupont
Florence Dupont
GCGabriele Colasurdo
Gabriele Colasurdo
MEMartine Elia
Martine Elia
JLJean Lachaine
Jean Lachaine
Background: Validated patient- and caregiver-reported outcome (PRO and CRO) questionnaires are widely used to assess quality of life (QoL) in multiple myeloma (MM). However, most were developed before recent therapeutic advances that have modified disease trajectories and may no longer fully reflect patients’ and caregivers’ experiences. Methods: A Canadian cross-sectional observational study was conducted in collaboration with the PROxy Network and Myeloma Canada. Patients with MM completed the EORTC QLQ-C30, EORTC QLQ-MY20, EQ-5D-5L, and ESAS-R questionnaires and caregivers of patients with MM completed the CarGOQoL. Both groups rated their perceived QoL using a numerical rating scale. The strength of associations between validated questionnaire global scores and self-perceived QoL was assessed using Spearman’s correlation coefficient (r). Results: Between October 2024 and February 2025, the study enrolled 305 patients and 104 caregivers. Moderate correlations were observed between patients’ perceived QoL and validated PRO global scores (range of r: 0.59 to 0.65). The MM-specific QLQ-MY20 showed one of the lowest correlations (r = 0.59; 95% confidence interval (CI) 0.51–0.66; p < 0.001). The caregiver-reported CarGOQoL also demonstrated a moderate association (r = 0.54; 95% CI 0.38–0.67; p < 0.001). Conclusions: Contemporary treatment advances, including prolonged survival and evolving side effect profiles, may not be reflected in currently available PRO and CRO instruments.